DiaCarta, Inc.
PrivateLast Round
Reverse Merger
Oct 14, 2022
Total Funding Raised
$55.6M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
DiaCarta, Inc. is a biotechnology company that develops and provides precision molecular diagnostic tests and services for oncology and infectious diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Medical Devices, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
DiaCarta, Inc. Comparables
Compare DiaCarta, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Predicine | 86% | |
| Lucence | 83% | |
| Datar Cancer Genetics | 79% | |
DiaCarta, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Reverse Merger | Oct 14, 2022 | ||||
| Grant | Oct 15, 2018 | ||||
| Grant | Jun 1, 2018 | ||||
| Series B | Feb 12, 2018 | ||||
| Grant | Oct 26, 2016 | ||||
Series A | Jan 9, 2015 |
DiaCarta, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| Fortune Fountain Capital | Series B |
| BVCF | Series A |
| HH&L Acquisition Co. | Reverse Merger |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 20, 2026
Open roles increased to 35, representing 97% of headcount.
- Jan 20, 2026
Monthly visitors increased 113% MoM, reaching 3.4K.
DiaCarta, Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about DiaCarta, Inc.'s valuation, stock price, and market status.